Suppressive effect of RAS inhibitor manumycin A on aberrant crypt foci formation in the azoxymethane-induced rat colorectal carcinogenesis model

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 10, 2013, Pages 1616-1623

  Tsuda, Miho ^a   Okamoto, Koichi ^a   Muguruma, Naoki ^a   Sannomiya, Katsutaka ^a   Nakagawa, Tadahiko ^a   Miyamoto, Hiroshi ^a   Kitamura, Shinji ^a   Goji, Takahiro ^a   Kimura, Tetsuo ^a   Okahisa, Toshiya ^a   Izumi, Keisuke ^a   Takayama, Tetsuji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Aberrant crypt foci; Colorectal cancer; Manumycin A cancer prevention; RAS inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; AZOXYMETHANE; KI 67 ANTIGEN; MANUMYCIN A; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG;

ABERRANT CRYPT FOCUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

ABERRANT CRYPT FOCI; COLORECTAL CANCER; MANUMYCIN A CANCER PREVENTION; RAS INHIBITOR;

ABERRANT CRYPT FOCI; ANIMALS; APOPTOSIS; AZOXYMETHANE; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FARNESYLTRANSTRANSFERASE; GENES, RAS; INJECTIONS, SUBCUTANEOUS; KI-67 ANTIGEN; MUTATION; PHOSPHORYLATION; POLYENES; POLYUNSATURATED ALKAMIDES; RAS PROTEINS; RATS; RATS, INBRED F344;

EID: 84897624506     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12287     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012; 62: 10-29.
2. Baron JA, Cole BF, Sandler RS etal. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 2003; 348: 891-899.
3. Sandler RS, Halabi S, Baron JA etal. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 2003; 348: 883-890.
4. Labayle D, Fischer D, Vielh P etal. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635-639.
5. Arber N, Eagle CJ, Spicak J etal. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 2006; 355: 885-895.
6. Bertagnolli MM, Eagle CJ, Zauber AG etal. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 2006; 355: 873-884.
7. Solomon SD, Wittes J, Finn PV etal. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials-the cross trial safety analysis. Circulation 2008; 117: 2104-2113.
8. Vogelstein B, Fearon ER, Hamilton SR etal. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988; 319: 525-532.
9. Scott N, Bell SM, Sagar P, Blair GE, Dixon MF, Quirke P. p53 expression and K-ras mutation in colorectal adenomas. Gut 1993; 34: 621-624.
10. Takayama T, Ohi M, Hayashi T etal. Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology 2001; 121: 599-611.
11. Kimura T, Okamoto K, Miyamoto H etal. Clinical benefit of high-sensitivity KRAS mutation testing in metastatic colorectal cancer treated with anti-EGFR antibody therapy. Oncology 2012; 82: 298-304.
12. Takayama T, Katsuki S, Takahashi Y etal. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N. Engl. J. Med. 1998; 339: 1277-1284.
13. Otori K, Konishi M, Sugiyama K etal. Infrequent somatic mutation of the adenomatous polyposis coli gene in aberrant crypt foci of human colon tissue. Cancer 1998; 83: 896-900.
14. Miyanishi K, Takayama T, Ohi M etal. Glutathione S-transferase-pi overexpression is closely associated with K-ras mutation during human colon carcinogenesis. Gastroenterology 2001; 121: 865-874.
15. Hara M, Akasaka K, Akinaga S etal. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc. Natl Acad. Sci. U. S. A. 1993; 90: 2281-2285.
16. Hara M, Han M. RAS Farnesyltransferase inhibitors suppress the phenotype resulting from an activated RAS mutation in Caenorhabditis elegans. Proc. Natl Acad. Sci. U. S. A. 1995; 92: 3333-3337.
17. Kainuma O, Asano T, Hasegawa M etal. Inhibition of growth and invasive activity of human pancreatic cancer cells by a farnesyltransferase inhibitor, manumycin. Pancreas 1997; 15: 379-383.
18. Zhou JM, Zhu XF, Pan QC, Liao DF, Li ZM, Liu ZC. Manumycin inhibits cell proliferation and the Ras signal transduction pathway in human hepatocellular carcinoma cells. Int. J. Mol. Med. 2003; 11: 767-771.
19. Pan JX, Yeung SCJ. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res. 2005; 65: 9109-9112.
20. Servais P, Gulbis B, Fokan D, Galand P. Effects of the farnesyltransferase inhibitor UCF-1C/manumycin on growth and p21-ras post-translational processing in NIH3T3 cells. Int. J. Cancer 1998; 76: 601-608.
21. Nagase T, Kawata S, Tamura S etal. Inhibition of cell growth of human hepatoma cell line (Hep G2) by a farnesyl protein transferase inhibitor: a preferential suppression of ras farnesylation. Int. J. Cancer 1996; 65: 620-626.
22. Zhou JM, Zhu XF, Pan QC, Liao DF, Li ZM, Liu ZC. Manumycin induces apoptosis in human hepatocellular carcinoma HepG2 cells. Int. J. Mol. Med. 2003; 12: 955-959.
23. Di Paolo A, Danesi R, Nardini D etal. Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells. Br. J. Cancer 2000; 82: 905-912.
24. Singha PK, Pandeswara S, Venkatachalam MA, Saikumar P. Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death. Cell Death Dis. 2013; 4: e457.
25. Jamroz-Wiśniewska A, Wójcicka G, Lowicka E, Ksiazek M, Beltowski J. Transactivation of epidermal growth factor receptor in vascular and renal systems in rats with experimental hyperleptinemia: role in leptin-induced hypertension. Biochem. Pharmacol. 2008; 75: 1623-1638.
26. Takeuchi H, Kimura T, Okamoto K etal. A mechanism for abnormal angiogenesis in human radiation proctitis: analysis of expression profile for angiogenic factors. J. Gastroenterol. 2012; 47: 56-64.
27. Lantry LE, Zhang ZQ, Crist KA etal. Chemopreventive efficacy of promising farnesyltransferase inhibitors. Exp. Lung Res. 2000; 26: 773-790.
28. McLellan EA, Medline A, Bird RP. Sequential analyses of the growth and morphological characteristics of aberrant crypt foci: putative preneoplastic lesions. Cancer Res. 1991; 51: 5270-5274.
29. Seike K, Koda K, Oda K etal. Assessment of rectal aberrant crypt foci by standard chromoscopy and its predictive value for colonic advanced neoplasms. Am. J. Gastroenterol. 2006; 101: 1362-1369.
30. Hurlstone DP, Karajeh M, Sanders DS, Drew K, Cross SS. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia. Am. J. Gastroenterol. 2005; 100: 1283-1289.
31. Takayama T, Nagashima H, Maeda M etal. Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. Clin. Cancer Res. 2011; 17: 3803-3811.
32. Aviello G, Romano B, Borrelli F etal. Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med (Berl) 2012; 90: 925-934.
33. Dougherty U, Sehdev A, Cerda S etal. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin. Cancer Res. 2008; 14: 2253-2262.
34. Takahashi M, Wakabayashi K. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci. 2004; 95: 475-480.
35. Xiao H, Hao X, Simi B etal. Green tea polyphenols inhibit colorectal aberrant crypt foci (ACF) formation and prevent oncogenic changes in dysplastic ACF in azoxymethane-treated F344 rats. Carcinogenesis 2008; 29: 113-119.
36. Pan J, Xu G, Yeung SC. Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. J. Clin. Endocrinol. Metab. 2001; 86: 4731-4740.
37. Sears KT, Daino H, Carey GB. Reactive oxygen species-dependent destruction of MEK and Akt in manumycin stimulated death of lymphoid tumor and myeloma cell lines. Int. J. Cancer 2008; 122: 1496-1505.
38. Xu G, Pan J, Martin C, Yeung SC. Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. J. Clin. Endocrinol. Metab. 2001; 86: 4731-4740.
39. Riely GJ, Johnson ML, Medina C etal. A phase II trial of salirasib in patients with lung adenocarcinomas with KRAS mutations. J. Thorac. Oncol. 2011; 6: 1435-1437.
40. Catalanotti F, Solit DB, Pulitzer MP etal. Phase II trial of MEK inhibitor selumetinib (AZD6244) in patients with BRAFV600E/K-mutated melanoma. Clin. Cancer Res. 2013; 19: 2257-2264.